Pros | ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | ![]() 5Y returns in the bottom 25% of the category. ![]() 3Y returns in the bottom 25% of the category. |
INDMoney rank | 6/8 | 8/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 12 Years | 5 Years | ||
Fund Size | 1057 Cr | 755 Cr | ||
Min Investment | SIP ₹500 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹1000 | ||
Expense Ratio | 1.23% | 1.1% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | S&P BSE Healthcare PR | S&P BSE Healthcare PR |
No of Holdings | 45 | 29 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (10.93%) Cipla Ltd (6.19%) Dr Reddy's Laboratories Ltd (4.57%) Ajanta Pharma Ltd (4.43%) Glenmark Pharmaceuticals Ltd (3.74%) | Sun Pharmaceuticals Industries Ltd (14.49%) Cipla Ltd (8.9%) Torrent Pharmaceuticals Ltd (7.6%) Abbott India Ltd (6.56%) Apollo Hospitals Enterprise Ltd (5.93%) | ||
No of Sectors | 2 | 2 | ||
Top 3 Sectors | Health (98.66%) Basic Materials (1.34%) | Health (99.2%) Basic Materials (0.8%) | ||
Equity % | 99.55% | 98.62% | ||
Debt % | - | - | ||
P/E | 34.67 | 35.19 | ||
P/B | 5.43 | 5.89 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 6.66% | 5.92% | ||
3-Month Return | -9.76% | -9.74% | ||
6-Month Return | -8.63% | -9.82% | ||
1-Year Return | 18.18% | 9.92% | ||
3-Year Return | 20.13% | 18.34% | ||
5-Year Return | 28.62% | 25.95% |
Sharpe | 0.84 | 0.74 | ||
Alpha | 1.26 | -0.56 | ||
Beta | 0.96 | 0.96 | ||
Standard Deviation | 16.7 | 16.88 | ||
Information Ratio | 0.31 | -0.34 |
Description | UTI Healthcare Fund-Growth Option- Direct is an equity fund.The fund could potentially beat inflation in the long-run. | Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | - | Dhaval Shah |